Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE project
Author
Garcia Quesada, Maria
Yang, Yangyupei
Bennett, Julia C.
Hayford, Kyla
Zeger, Scott L.
Feikin, Daniel R.
Peterson, Meagan E.
Cohen, Adam L.
Almeida, Samanta C. G.
Ampofo, Krow
Ang, Michelle
Bar-Zeev, Naor
Bruce, Michael G.
Camilli, Romina
Chanto Chacón, Grettel
Ciruela, Pilar
Cohen, Cheryl
Corcoran, Mary
Dagan, Ron
De Wals, Philippe
Desmet, Stefanie
Diawara, Idrissa
Gierke, Ryan
Guevara, Marcela
Hammitt, Laura L.
Hilty, Markus
Ho, Pak-Leung
Jayasinghe, Sanjay
Kleynhans, Jackie
Kristinsson, Karl G.
Ladhani, Shamez N.
McGeer, Allison
Mwenda, Jason M.
Nuort, J. Pekka
Oishi, Kazunori
Ricketson, Leah J.
Sanz, Juan Carlos
Savrasova, Larisa
Setchanova, Lena Petrova
Smith, Andrew
Valentiner-Branth, Palle
Valenzuela, Maria Teresa
Van der Linden, Mark
Van Sorge, Nina M.
Varon, Emmanuelle
Winje, Brita A.
Yildirim, Inci
Zintgraff, Jonathan
Knoll, Maria Deloria
PSERENADE Team
Publication date
2021ISSN
2076-2607
Abstract
Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5–7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
61 - Medicina
Keywords
Meningitis
Vacunació dels infants
Pneumococs
Meningitis
Vacunación infantil
Streptococcus pneumoniae
Meningitis
Vaccination of infants
Pneumococcus
Pages
21
Publisher
MDPI
Collection
9;4
Is part of
Microorganisms
Citation
Garcia Quesada, Maria; Yang, Yangyupei; Bennett, Julia C. [et al.]. Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE project. Microorganisms, 2021, 9(4), 738. Disponible en: <https://www.mdpi.com/2076-2607/9/4/738>. Fecha de acceso: 13 abr. 2021. DOI: 10.3390/microorganisms9040738
This item appears in the following Collection(s)
- Ciències de la Salut [532]
Rights
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/